Reata Pharmaceuticals (Reata Pharmaceuticals) Risk Assessment

View and export this data going back to 2016. Start your Free Trial

What is Reata Pharmaceuticals Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Reata Pharmaceuticals is: No Data: Cannot be evaluated.

Competitive Comparison of Reata Pharmaceuticals's Risk Assessment

For the Biotechnology subindustry, Reata Pharmaceuticals's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Reata Pharmaceuticals's Risk Assessment Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Reata Pharmaceuticals's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Reata Pharmaceuticals's Risk Assessment falls into.

Reata Pharmaceuticals (NAS:RETA) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Reata Pharmaceuticals Risk Assessment Related Terms

Thank you for viewing the detailed overview of Reata Pharmaceuticals's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Reata Pharmaceuticals (Reata Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Reata Pharmaceuticals Inc (NAS:RETA) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

5320 Legacy Drive, Plano, TX, USA, 75024

Website

https://www.reatapharma.com

Reata Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing therapeutics to address serious and life-threatening diseases by targeting molecular pathways. The company's product in the pipeline include bardoxolone methyl; Omaveloxolone and others.

Executives

Steven Ryder	director	234 CHURCH STREET, SUITE 1020, NEW HAVEN CT 06510
Antal Rohit Desai	director, 10 percent owner	C/O PROCEPT BIOROBOTICS CORPORATION, 900 ISLAND DRIVE, REDWOOD CITY CA 94065
Rajiv Patni	officer: EVP, Chief R&D Officer	C/O OCERA THERAPEUTICS, INC., 525 UNIVERSITY AVENUE, SUITE 610, PALO ALTO CA 94301
Bhaskar Anand	officer: SVP, Chief Accounting Officer	5320 LEGACY DRIVE, PLANO TX 75024
Manmeet Singh Soni	officer: COO, CFO and President	C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE, SUNNYVALE CA 94085
Martin Edwards	director	15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803
Dawn Carter Bir	officer: Chief Commercial Officer	C/O REATA PHARMACEUTICALS, INC., 2801 GATEWAY DRIVE, SUITE 150, IRVING TX 75063
Christy J. Oliger	director	85 WELLS AVENUE, SUITE 210, NEWTON MA 02459
Andrea Loewen	officer: SVP, Global Regulatory Affairs	C/O VITAL THERAPIES, INC., 15010 AVENUE OF SCIENCE, SUITE 200, SAN DIEGO CA 92128
Shamim Ruff	director	215 FIRST STREET, SUITE 415, CAMBRIDGE MA 02142
Mcclellan William D. Jr.	director	C/O APOLLO ENDOSURGERY, INC., 1120 S., CAPITAL OF TEXAS HWY, BLDG. 1, SUITE 300, AUSTIN TX 78746
Michael D Wortley	officer: See Remarks	5320 LEGACY DRIVE, PLANO TX 75024
Meyer Colin John	officer: See Remarks	C/O REATA PHARMACEUTICALS, INC., 2801 GATEWAY DR. SUITE 150, IRVING TX 75063
Biogen Inc.	other: See footnotes	225 BINNEY STREET, CAMBRIDGE MA 02142
Samina Khan	officer: SVP, Chief Medical Officer	5320 LEGACY DRIVE, PLANO TX 75024